Physician profile
Ashley E Toole
NPI 1659668531
$1,824.38
in general payments reported to CMS, 2019-2025
25 companies · $222 in 2025
The $222 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $256 · 2021: $376 · 2022: $138 · 2023: $51.52 · 2024: $66.07 · 2025: $222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $339.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $445.36 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $149.39 | 2019-2024 | Farxiga |
| Insmed, INC. | $133.75 | 2019-2021 | |
| Abbvie INC. | $115.60 | 2021-2022 | |
| Astellas Pharma US INC | $105.18 | 2019-2021 | |
| Abiomed | $90.30 | 2025 | |
| Insulet Corporation | $87.58 | 2019-2023 | Omnipod |
| Allergan, INC. | $79.19 | 2019-2020 | |
| Mannkind Corporation | $77.30 | 2019-2021 | |
| Lilly USA, LLC | $77.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $64.63 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $55.00 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $52.77 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $50.65 | 2019 | |
| Amgen INC. | $44.41 | 2019-2024 | Otezla, Repatha |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.56 | 2019 | |
| Pfizer INC. | $28.84 | 2020-2024 | |
| Glaxosmithkline, LLC. | $27.36 | 2020-2021 | |
| Xeris Pharmaceuticals, INC. | $20.47 | 2022 | |
| Zealand Pharma US, INC. | $19.97 | 2021 | |
| Medtronic Minimed, INC. | $15.94 | 2020 | |
| Amarin Pharma, INC. | $15.73 | 2020 | |
| Abbott Laboratories | $12.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.40 | 2021 | |
| Gilead Sciences, INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Toole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.